Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604801 | 0.91 | ALDH1A1 (0.49) | RAB9ANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6603502 | 0.87 | MAPT (0.56) | RAB9ANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL144112 | 0.85 | ALDH1A1 (0.45) | RAB9ANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL143053 | 0.84 | MAOB (0.50) | CYP2C19HTTMAPTALDH1A1GAA | |
| SCHEMBL145108 | 0.82 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL6600744 | 0.81 | AHR (0.61) | RAB9ANPC1CYP1A2CYP3A4HTT | |
| SCHEMBL6606418 | 0.81 | MAPT (0.50) | RAB9ANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6604062 | 0.80 | MAPT (0.48) | RAB9ANPC1MAPTTSHRALDH1A1 | |
| SCHEMBL146917 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAAPGRHPGDPOLB | |
| SCHEMBL144189 | 0.80 | ALDH1A1 (0.45) | CYP1A2CYP2C9CYP2C19MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-0922036-B1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GMBH (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-6479494-B1 | THEY INHIBIT SELECTIVELY PHOSPHODIESTERASE IV, WHICH CAUSES AN INCREASE OF THE INTRACELLULAR CAMP LEVEL AS CAMP INHIBITS BONE DECREASING CELLS AND STIMULATES BONE INCREASING CELLS FOR TREATMENT OF OSTEOPOROSIS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6107295-A | Arylalkanoyl pyridazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | RAB9A 2690/4885NPC1 2593/4885CYP1A2 4682/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | RAB9A 2690/4885NPC1 2593/4885CYP1A2 4682/4885 |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | PDE4A, PDE4B, PDE12 | RAB9A 1923/4885NPC1 3737/4885CYP1A2 680/4885 |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | PDE4A, PDE4B, PDE4C | RAB9A 2408/4885NPC1 3669/4885CYP1A2 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.